Wolfgang M Brückl (Wolfgang M Brueckl)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Topics

Intellectual Disability

Clinical Practice

Epidermal Growth Factor Receptor

Cross Sectional

Top Venues

Current oncology (Toronto, Ont.)

Therapeutic advances in medical oncology

Clinical Medicine Insights. Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Markus Falk, Stefanie Schatz, Fabian P M Reich, Stefanie Schmidt, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Current oncology (Toronto, Ont.) 30 (10) (2023)
Markus Falk, Eva Willing, Stefanie Schmidt, Stefanie Schatz, Marco Galster, Markus Tiemann, Joachim H Ficker, Wolfgang M Brückl
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current oncology (Toronto, Ont.) 30 (2) (2023)
Martin Faehling, Hanno Witte, Martin Sebastian, Matthias Ulmer, Rainer Sätzler, Konrad Steinestel, Wolfgang M Brückl, Georg Evers, Christian Meyer Zum Büschenfelde, Annalen Bleckmann
Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP). Therapeutic advances in medical oncology 14 (2022)
Wolfgang M Brückl, Martin Reck, Frank Griesinger, Harald Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Joachim H Ficker, Christopher Hoffmann, Andrea Schüler, Eckart Laack
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Therapeutic advances in medical oncology 13 (2021)
Jakob Michael Riedl, Dominik Andreas Barth, Wolfgang M Brückl, Gloria Zeitler, Vasile Foris, Stefanie Mollnar, Michael Stotz, Christopher H Rossmann, Angelika Terbuch, Marija Balić, Tobias Niedrist, Thomas Bertsch, Herbert Stoeger, Martin Pichler, Horst Olschewski, Gudrun Absenger, Joachim H Ficker, Armin Gerger, Florian Posch
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Cancers 12 (8) (2020)
Wolfgang M Brückl, Joachim H Ficker, Gloria Zeitler
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC cancer 20 (1) (2020)
Wolfgang M Brückl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H Ficker, Eckart Laack
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clinical Medicine Insights. Oncology 14 (2020)